CD19 and B-cell chronic lymphocytic leukemia: In another phase 2 prospective trial, Gill et al. investigated the safety and efficacy of combining anti-CD19 CAR T-cell therapy with a humanized binding domain (huCAR T) and ibrutinib in R/R CLL after at least 6 months of ibrutinib (Table 2).57